1.0ZoBio - Drug Discovery Technologyhttps://zobio.com/onlineContent manager ~KBhttps://zobio.com/online/author/kasia/YTHDF2 – An unprecedented epitranscriptomic reader protein - ZoBio - Drug Discovery Technologyrich600338<blockquote class="wp-embedded-content" data-secret="weSEvOfN70"><a href="https://zobio.com/online/cases/ythdf2-an-unprecedented-epitranscriptomic-reader-protein/">YTHDF2 – An unprecedented epitranscriptomic reader protein</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://zobio.com/online/cases/ythdf2-an-unprecedented-epitranscriptomic-reader-protein/embed/#?secret=weSEvOfN70" width="600" height="338" title="“YTHDF2 – An unprecedented epitranscriptomic reader protein” — ZoBio - Drug Discovery Technology" data-secret="weSEvOfN70" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript">
/* <![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://zobio.com/online/wp-includes/js/wp-embed.min.js
/* ]]> */
</script>
https://zobio.com/online/wp-content/uploads/2020/01/JV7A9921-1-e1678356118107.jpg20001100Challenge Our client tasked us with setting up a complete “gene to lead” fragment-based drug discovery campaign. Since the entire family is unprecedented, there were no “tool compounds” typically required to set up assays. As we progressed, further challenges presented themselves. Achievements By capitalizing on our unique expertise in developing customized biophysical assays, we created a biologically relevant compound screening cascade in the absence of tool compounds. The cascade delivered chemically diverse sets of validated fragments that we successfully elaborated towards lead compounds using structural information that could only be gleaned through NMR.